Literature DB >> 22169441

¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

Golam M I Chowdhury1, Kevin L Behar, William Cho, Monique A Thomas, Douglas L Rothman, Gerard Sanacora.   

Abstract

Ketamine has recently gained significant attention owing to its psychotomimetic and more recently discovered rapid antidepressant-like properties. ¹H-[¹³C]-nuclear magnetic resonance studies were employed to explore potential physiological processes underlying these unique effects. [1-¹³C]glucose and [2-¹³C]acetate-nuclear magnetic resonance ex vivo studies were performed on the medial prefrontal cortex (mPFC) and hippocampus of rats acutely treated with 30 mg/kg or 80 mg/kg ketamine and compared with saline-treated animals to determine the effects of ketamine on amino acid neurotransmitter cycling and glial metabolism. A subanesthetic, but not anesthetic, dose of ketamine significantly increased the percentage of ¹³C-enrichments of glutamate, γ-aminobutyric acid, and glutamine in the mPFC of rats. Subanesthetic doses of ketamine increased mPFC amino acid neurotransmitter cycling, as well as neuronal and glial energy metabolism. These data add to previous reports suggesting increased mPFC levels of glutamate release, following the administration of subanesthetic doses of ketamine, are related to the drug's acute effects on cognition, perception, and mood.
Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169441      PMCID: PMC3660962          DOI: 10.1016/j.biopsych.2011.11.006

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  34 in total

1.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

Authors:  Laura M Rowland; Juan R Bustillo; Paul G Mullins; Rex E Jung; Rhoshel Lenroot; Elma Landgraf; Ranee Barrow; Ronald Yeo; John Lauriello; William M Brooks
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

2.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

3.  Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation.

Authors:  Gary E Duncan; Seiya Miyamoto; Jeffrey A Lieberman
Journal:  J Pharmacol Exp Ther       Date:  2003-03-06       Impact factor: 4.030

4.  The contribution of GABA to glutamate/glutamine cycling and energy metabolism in the rat cortex in vivo.

Authors:  Anant B Patel; Robin A de Graaf; Graeme F Mason; Douglas L Rothman; Robert G Shulman; Kevin L Behar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

5.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.

Authors:  A Breier; A K Malhotra; D A Pinals; N I Weisenfeld; D Pickar
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

6.  Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia.

Authors:  G E Duncan; S S Moy; D J Knapp; R A Mueller; G R Breese
Journal:  Brain Res       Date:  1998-03-23       Impact factor: 3.252

7.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

8.  Mapping the central effects of ketamine in the rat using pharmacological MRI.

Authors:  Clare L Littlewood; Nicholas Jones; Michael J O'Neill; Stephen N Mitchell; Mark Tricklebank; Steven C R Williams
Journal:  Psychopharmacology (Berl)       Date:  2006-03-21       Impact factor: 4.530

9.  Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.

Authors:  John H Krystal; Walid Abi-Saab; Edward Perry; D Cyril D'Souza; Nianjin Liu; Ralitza Gueorguieva; Lisa McDougall; Tracy Hunsberger; Aysenil Belger; Louise Levine; Alan Breier
Journal:  Psychopharmacology (Berl)       Date:  2004-08-10       Impact factor: 4.530

10.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate.

Authors:  N A Anis; S C Berry; N R Burton; D Lodge
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

View more
  56 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

Authors:  Christine DeLorenzo; Nicole DellaGioia; Michael Bloch; Gerard Sanacora; Nabeel Nabulsi; Chadi Abdallah; Jie Yang; Ruofeng Wen; J John Mann; John H Krystal; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  Biol Psychiatry       Date:  2014-07-10       Impact factor: 13.382

Review 3.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

4.  Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.

Authors:  Qi Zhang; Fei Guo; Zhi-wen Fu; Bing Zhang; Cheng-gang Huang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

Review 5.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

6.  In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB.

Authors:  Christine DeLorenzo; Jean-Dominique Gallezot; John Gardus; Jie Yang; Beata Planeta; Nabeel Nabulsi; R Todd Ogden; David C Labaree; Yiyun H Huang; J John Mann; Fabrizio Gasparini; Xin Lin; Jonathan A Javitch; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

7.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

Review 8.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

9.  Studies of the metabotropic glutamate receptor 5 radioligand [¹¹C]ABP688 with N-acetylcysteine challenge in rhesus monkeys.

Authors:  Christine M Sandiego; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Soheila Najafzadeh; Yiyun Huang; Kelly Cosgrove; Richard E Carson
Journal:  Synapse       Date:  2013-03-27       Impact factor: 2.562

10.  Glutamine/glutamate (Glx) concentration in prefrontal cortex predicts reversal learning performance in the marmoset.

Authors:  Agnès Lacreuse; Constance M Moore; Matthew LaClair; Laurellee Payne; Jean A King
Journal:  Behav Brain Res       Date:  2018-01-31       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.